Výsledky vyhledávání - "Michael W Konstan"

Akademický článek

Assessing Priorities in a Statewide Cardiovascular and Diabetes Health Collaborative Based on the Results of a Needs Assessment: Cross-Sectional Survey Study

Autor: Elizabeth A Beverly, Sarah Koopman-Gonzalez, Jackson Wright, Kathleen Dungan, Harini Pallerla, Rose Gubitosi-Klug, Kristin Baughman, Michael W Konstan, Shari D Bolen

Publikováno v: JMIR Formative Research, Vol 8, p e55285 (2024)

BackgroundThe Ohio Cardiovascular and Diabetes Health Collaborative (Cardi-OH) unites general and subspecialty medical staff at the 7 medical schools in Ohio with community and public health partnerships to improve cardiovascular and diabetes health

Externí odkaz: https://doaj.org/article/ef6e24395eea4b6d9b652ad3db09db32

Zobrazit plný text záznamu

Akademický článek

Genomic heterogeneity underlies multidrug resistance in Pseudomonas aeruginosa: A population-level analysis beyond susceptibility testing.

Publikováno v: PLoS ONE, Vol 17, Iss 3, p e0265129 (2022)

BackgroundPseudomonas aeruginosa is a persistent and difficult-to-treat pathogen in many patients, especially those with Cystic Fibrosis (CF). Herein, we describe a longitudinal analysis of a series of multidrug resistant (MDR) P. aeruginosa isolates

Externí odkaz: https://doaj.org/article/b792cfbcd3cf4cadae6ebcb48376470a

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

Normalized T1 magnetic resonance imaging for assessment of regional lung function in adult cystic fibrosis patients--a cross-sectional study.

Autor: Elliott C Dasenbrook, Lan Lu, Shannon Donnola, David E Weaver, Vikas Gulani, Peter M Jakob, Michael W Konstan, Chris A Flask

Publikováno v: PLoS ONE, Vol 8, Iss 9, p e73286 (2013)

Cystic fibrosis (CF) patients would benefit from a safe and effective tool to detect early-stage, regional lung disease to allow for early intervention. Magnetic Resonance Imaging (MRI) is a safe, non-invasive procedure capable of providing quantitat

Externí odkaz: https://doaj.org/article/d3fa1bd5c4bc49849ee2703bca815ce7

Zobrazit plný text záznamu

Rate of Lung Function Decline in People with Cystic Fibrosis Having a Residual Function Gene Mutation

Autor: Gregory S. Sawicki, Michael W. Konstan, Edward F. McKone, Richard B. Moss, Barry Lubarsky, Ellison Suthoff, Stefanie J. Millar, David J. Pasta, Nicole Mayer-Hamblett, Christopher H. Goss, Wayne J. Morgan, Margaret E. Duncan, Yoojung Yang

Publikováno v: Pulmonary Therapy. 8:385-395

Cystic fibrosis (CF) is an autosomal recessive disease caused by mutations in the CF transmembrane conductance regulator (CFTR) gene. Approximately 5% of people with CF have residual function (RF) CFTR mutations that result in partially retained CFTR

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2fecbc7a94f623fdbb7679fee587a622
https://doi.org/10.1007/s41030-022-00202-y

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

Modeling long-term health outcomes of patients with cystic fibrosis homozygous for treated with lumacaftor/ivacaftor

Autor: Jaime L. Rubin, Lasair O’Callaghan, Christopher Pelligra, Michael W. Konstan, Alexandra Ward, Jack K. Ishak, Conor Chandler, Theodore G. Liou

Publikováno v: Therapeutic Advances in Respiratory Disease, Vol 13 (2019)

Background: Lumacaftor/ivacaftor combination therapy is efficacious and generally safe for patients with cystic fibrosis (CF) homozygous for the F508del-CF transmembrane conductance regulator (CFTR) mutation. However, long-term survival benefits of l

Externí odkaz: https://doaj.org/article/ca5470f6683f4039843231b8785b87d8

Zobrazit plný text záznamu

Disease burden in people with cystic fibrosis heterozygous for F508del and a minimal function mutation

Autor: Kate Van Brunt, Michael W. Konstan, Jason Booth, Stefanie J. Millar, Gregory S. Sawicki, Evan Bailey, Patrick A. Flume

Publikováno v: J Cyst Fibros

Background People with cystic fibrosis (CF) heterozygous for F508del-CFTR and a minimal function CFTR mutation (F/MF) that results in no CFTR protein or results in CFTR protein that is not responsive to tezacaftor, ivacaftor, and tezacaftor/ivacaftor

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aab14a647bff57fedb44271bbbafa139
https://doi.org/10.1016/j.jcf.2021.07.003

Zobrazit plný text záznamu

Empire-CF study: A phase 2 clinical trial of leukotriene A4 hydrolase inhibitor acebilustat in adult subjects with cystic fibrosis

Autor: Sanjeev Ahuja, R. Grosswald, Ahmet Uluer, Alex Horsley, Shawn D. Aaron, John Mershon, J. Stuart Elborn, Cori L. Daines, Steven M. Rowe, Eric Springman, Isabelle Fajac, Jennifer L. Taylor-Cousar, Sivagurunathan Sutharsan, Vincenzina Lucidi, Damian G Downey, Michael W. Konstan

Publikováno v: EMPIRE-CF study group 2021, ' Empire-CF study: A phase 2 clinical trial of leukotriene A4 hydrolase inhibitor acebilustat in adult subjects with cystic fibrosis ', Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society . https://doi.org/10.1016/j.jcf.2021.08.007
Elborn, J S, Konstan, M W, Taylor-cousar, J L, Fajac, I, Horsley, A, Sutharsan, S, Aaron, S D, Daines, C L, Uluer, A, Downey, D G, Lucidi, V V, Ahuja, S, Springman, E, Mershon, J, Grosswald, R & Rowe, S M 2021, ' Empire-CF study: A phase 2 clinical trial of leukotriene A4 hydrolase inhibitor acebilustat in adult subjects with cystic fibrosis ', Journal of Cystic Fibrosis . https://doi.org/10.1016/j.jcf.2021.08.007
J Cyst Fibros

BACKGROUND: Cystic fibrosis (CF) is characterized by neutrophilic inflammation in the airways. Leukotriene B4 (LTB4) is a neutrophil chemoattractant and has been implicated in CF pathogenesis. Acebilustat, a novel, synthetic, small-molecule leukotrie

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b6d5cbf341123ffff9992081e19ae567
https://doi.org/10.1016/j.jcf.2021.08.007

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání